Chapter 32: HIV & AIDS Antiretroviral Drug Therapy

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today, we are opening up a chapter that really represents one of the most profound shifts in modern medicine.

It's a huge one.

We are looking at Chapter 32 of pharmacology,

a patient -centered nursing process approach, the 12th edition.

And the topic is HIV and Aids Reloaded Drugs.

Yeah, it's a massive topic.

I mean, if you just look back 40 years, a diagnosis of HIV was, it was essentially a terminal prognosis.

A death sentence.

It really was.

It was a question of when, not if.

And today, thanks to the very pharmacology we're about to discuss, it's been transformed into a manageable chronic condition.

That's just incredible.

It's a huge triumph of science, but you know, it puts a heavy burden of knowledge on the nurse.

That is exactly what we're here to unpack.

We know our audience ranges from nursing students facing their first FARM exam to seasoned clinicians who just want a refresher.

Our mission today is to take this really dense chapter.

I mean, it's full of viral mechanics, heavy drug classes, complex interactions, and translate it all into clear, actionable clinical knowledge.

Yeah, we want to get past the Jorgens.

Exactly.

Get to the so what of it all, the stuff you actually use.

And we are going to stick strictly to the text of chapter 32.

We want to make sure you understand the classifications, the mechanisms, and you know, most importantly, the nursing implications that keep your patients safe.

Okay, so let's start with the big picture.

The text gives us some pretty sobering statistics just to set the stage.

We're looking at an epidemic that started, what, in the early 1980s?

That's right.

And if we look at where we stand now, well, the text notes that over one million people in the United States are currently infected with HIV.

One million.

And in 2021 alone, there were over 36 ,000 new diagnoses.

Now the authors do point out, you know, that number might be slightly skewed.

Because of COVID.

Exactly.

The COVID -19 pandemic disrupted a lot of testing centers, but still the volume is significant.

And there's a specific gap the text highlights this undiagnosed population.

Right.

So the CDC reports that about 87 % of people with HIV know their status.

That sounds pretty good on the surface.

It sounds like a high number until you do the math on the inverse, right?

That leaves 13 % of people who are living with HIV, but they just don't know it.

Wow.

That is a significant number of people who aren't getting treatment and who could be, you know, unknowingly transmitting the virus.

Which is why understanding this stuff is so critical to close that gap.

Yeah.

So here's our roadmap for this deep dive.

We're going to start with the why, the pathophysiology of the virus itself.

You have to know the enemy to beat it.

Then we're going deep, deep into the drug classifications.

We'll break down the NRTIs, the NNRTIs, the protease inhibitors, and all the newer classes.

And for each class, we're not just going to list side effects from a book.

We're going to connect them to what a nurse actually sees, what you'll actually do at the bedside.

Exactly.

And then finally, we'll wrap up with the nurse's role adherence, which is the golden rule here, and special populations like pregnancy.

Sounds like a plan.

So let's unpack the virus itself,

HIV.

What are we actually really dealing with here?

So HIV is an RNA retrovirus.

Now, to understand the drugs, you really have to understand this fundamental flaw in the virus.

It's parasitic.

Parasitic.

In the truest sense, it cannot survive and it certainly cannot replicate unless it gets inside a living human cell.

It's a hijacker.

A hijacker.

I like that analogy.

It's simple and it has a very specific target, right?

It doesn't just infect any cell.

It does.

It targets the CD4 plus T cell.

You might also hear these called helper T cells or CD4 plus T lymphocytes.

I always think of these as the generals of the immune system army.

Is that a fair way to look at it?

That is a perfect way to visualize it.

These cells play a critical role in recognizing infectious processes, even cancers.

They direct the entire immune response.

Take all the shots.

They do.

So when HIV targets them, it's effectively taking out the command center.

The virus gets in, it destroys these CD4 cells, and that leads directly to immune deficiency.

And that deficiency is what opens the door for all those other horrible things.

Exactly.

The opportunistic infections.

It's important to remember, it's usually the opportunistic infections that are the real danger, not the virus itself directly.

The virus disables the shields and then something else.

A fungus, a bacteria, a cancer attacks the now defenseless body.

Okay, so if I'm a nurse or a patient for that matter, there are two numbers on my dashboard that I'm just obsessing over.

The CD4 count and the viral load.

Let's break these down.

Let's start with CD4.

Okay.

Think of the CD4 count as your defensive capability.

It's the best indicator of your immune function.

In a healthy person, a normal range is anywhere from say 500 to 1500 cells per cubic millimeter.

500 to 1500.

Got it.

Now, a key clinical tip from the text, and this is really important for practice.

Consistency matters.

The percentage of CD4 cells is actually more stable than the absolute count, but patients should be encouraged to use the same laboratory.

Oh, that makes sense.

And go at the same time of day for their blood draws.

Really?

The time of day actually matters.

It does.

There are physiologic changes throughout the day that can cause the count to fluctuate.

So to get a reliable trend, you really want to compare apples to apples.

Minimize all that variability.

That's a great tip.

Okay, so that's the defense.

Now, the second number, the viral load.

That's the enemy count.

That's it.

This is the plasma HIV RNA quantitative assay.

It's a mouthful, but this tells us how much virus is actually circulating in the blood.

And this is the best determinant of whether the treatment is actually working.

And the goal isn't just low, is it?

It's something more specific.

The goal is undetectable.

And in the text, what does undetectable technically mean?

Does it mean zero?

Not exactly zero.

It means the amount of virus is so low that the lab tests can't find it.

Depending on the sensitivity of that test, it usually means less than 40 to 75 copies per milliliter.

Okay.

But generally, the clinical benchmark for viral suppression is anything below 200 copies per milliliter.

And there is a huge, huge concept associated with this that the text highlights.

Undetectable equals untransmittable.

U equals U.

It's a massive concept for patient quality of life and for reducing stigma.

It's empowering.

If a patient is on their meds and they have a sustained undetectable viral load, they cannot sexually transmit the virus to others.

That changes everything.

It changes the entire narrative from fear and shame to management and control.

That is profound.

And the text says the goal is to reach that undetectable status pretty quickly after starting therapy.

Yes.

The goal is to reach an undetectable viral load within 16 to 24 weeks of starting.

If you don't hit that target, or if the viral load starts creeping back up later on, we have to look at two things.

Viral resistance or, much more likely, adherence issues.

Before we jump into the drugs, can we quickly walk through the stages of the infection?

Because it's not just you have HIV and that's it, right?

The disease has a timeline.

Right.

The CDC classifies it into three main stages.

Stage one is acute HIV infection.

This is right after exposure.

So what's happening physiologically here in stage one?

The viral load is sky high.

I mean, the virus is replicating massively.

But the body hasn't mounted a full antibody defense yet.

It's trying to figure out what's going on.

And this is the tricky part for diagnosis, right?

Yeah.

Because the symptoms are just so vague.

So vague.

It's often called acute retroviral syndrome or seroconversion.

And it feels just like the flu.

Fever, fatigue, night sweats, maybe a headache, a sore throat.

So a patient walks into an urgent care clinic, says, I feel achy and tired.

And unless the provider is really, really sharp and asks the right questions about risk factors.

They're just going to say, go home, drink fluids.

It's a virus.

Exactly.

And that's so dangerous because this is when the patient is highly infectious due to that incredibly high viral load.

And then there's this concept of the window period.

This is important.

Yeah, let's unpack that.

Between the time you get infected and the time a standard test can actually detect the antibodies your body makes, there's a delay.

How long?

It averages about 10 to 14 days.

But for some people, it can take three to four weeks.

And in some pretty rare cases, it can take up to six months to fully seroconvert.

So you could test negative on day 12, but actually be positive and infectious.

Yes, absolutely.

That is why if there's a high suspicion, say,

a known high risk exposure, and that initial antibody test is negative, we counsel them to repeat the test in three months.

Or is there another kind of test?

Yes, if we really suspect it, we can order a viral load test, which finds the genetic material of the virus itself, not just the antibodies.

It closes that window.

OK, so moving on to stage two, chronic HIV infection.

So the stage is often asymptomatic.

The viral load drops down quite a bit because the immune system is putting up a good fight, but the virus is still being produced.

The person is infectious, but they might feel totally fine for years.

And then stage three, AIDS.

This is the most severe stage.

Acquired immunodeficiency syndrome.

The immune system is just badly damaged.

The CD4 count drops significantly.

Usually the benchmark is below 200.

The viral load shoots back up, and the body becomes prone to all those opportunistic infections we mentioned.

And the prognosis there without treatment?

Without treatment, the survival rate at the stage is roughly three years.

Which is why catching it in stage one or two is so, so vital.

Now, I want to bust some myths real quick because the text is very specific about transmission.

Please, let's do that.

This is so important.

Okay, so we know it spreads through sexual contact, direct blood contact, like sharing needles,

and mother to child during pregnancy or breastfeeding.

But what does the text explicitly say it does not spread through?

Okay, it is not spread by air or water.

It's not spread by insects, including mosquitoes or ticks.

Mosquitoes.

Let's say that again.

Mosquitoes do not transmit HIV.

It's also not spread by saliva, tears, or sweat, unless there is visible blood mixed in.

And casual contact.

Not at all.

It is not spread by casual contact like shaking hands, hugging, sharing toilets, or sharing dishes.

That stigma is based on misinformation.

I feel like we can't say that enough.

Thank you.

Okay, so we know what the virus is, how it works, how it spreads.

Now, let's talk about how we fight it.

Section two,

the principles of art, antiretroviral therapy.

Right.

What are the high level goals here?

We have five main goals outlined in the text.

One, reduce morbidity and mortality.

Two, prolong the quality of life.

Three, restore immunologic function.

So get those CD4 cells back up.

Four, suppress the viral load.

And five, prevent transmission.

And who gets treated?

Is it only people with really low CD4 counts, like in stage three?

Not anymore.

That used to be the case years and years ago, but the current guidelines are crystal clear.

We treat everyone infected with HIV -1, regardless of their CD4 count.

So as soon as you're diagnosed.

We want you on meds.

The sooner, the better.

And we don't just give them one pill, right?

We always hear about this cocktail.

Why is that?

This brings us to the resistance challenge.

And to understand this, you need to know that HIV is a sloppy virus.

Sloppy.

What do you mean by that?

When it replicates, it makes a lot of mistakes copying its genetic code.

These mistakes are mutations.

So if you use just one drug monotherapy, the virus will just randomly mutate into a form that's resistant to that one drug.

And it happens fast.

Incredibly fast.

Because it replicates so quickly, that one resistant strain becomes the dominant one very, very quickly.

So if I'm only taking drug A, the virus learns how to beat drug A, and then drug A is useless.

Exactly.

But if I hit it with drug A, drug B, and drug C all at the same time, each with a different mechanism.

I see.

The statistical likelihood of the virus randomly mutating to beat all three of those mechanisms simultaneously

is infinitesimally small.

It can't keep up.

So the rule is never add a single drug to a failing regimen.

That is a recipe for instant resistance.

If a regimen is failing, you have to switch things up completely or add at least two, preferably three, new active drugs.

The standard for a treatment -naive patient, someone new to meds, is generally two NRTIs plus a third active drug from a different class.

OK.

Let's get into that alphabet soup.

The drug classes, this is the real meat of the chapter.

We're going to start with the backbone of therapy, the NRTIs.

The nucleoside and nucleotide reverse transcriptase inhibitors.

Or, as the cool kids say, the nukes.

The nukes.

I like it.

How do they work?

What's the mechanism?

So think of them as fake building blocks.

The virus needs to build a DNA chain to replicate itself from its RNA blueprint.

It uses an enzyme called reverse transcriptase to lay down the bricks, the building blocks.

NRTIs get into the cell, and they pretend to be natural, normal building blocks.

So the virus's little construction worker, the reverse transcriptase, picks up the NRTI, tries to put it in the wall.

And the wall collapses.

Or rather, construction just stops.

It inhibits the viral DNA polymerase, and it terminates the chain.

It's a dead end.

Got it.

OK.

Let's talk about the key players in this class.

First up, a bit of a history lesson from the text.

Zitovudin, ZDV.

Yes.

The first one, AZT.

It changed the game back in the 80s.

But, you know, like a lot of early technology, it comes with some serious baggage.

What kind of baggage are we talking about?

Bone marrow suppression.

That's the big one.

The really big one.

It can cause severe anemia and neutropenia.

So if a patient is on Zitovudin, you are watching their CBC, their complete blood count, like a hawk.

The text also mentions other symptoms, like headache and malaise.

Right.

It's just a heavy drug.

It requires very close administration and monitoring.

It's not used as much first line anymore, but it's historically so important.

Next up in the new category,

tenofovir disapropyl fumarate, or TDF.

This one seems very common in current regimens.

It is.

It's a workhorse.

But TDF has its own specific warning labels you have to know.

When you hear tenofovir, I want you to think about two specific organ systems,

the kidneys and the bones.

Kidneys and bones.

Why?

It can cause renal insufficiency, and in some cases, it can lead to acute renal failure or a specific condition called Fanconi syndrome.

And it's also linked to bone fractures and decreases in bone mineral density.

So for a patient with a history of osteoporosis or any renal issues, this requires very careful consideration.

Now, speaking of safety for the whole class of NRTIs, there's a very scary black box warning we need to discuss.

Lactic acidosis and severe hepatomegaly with steatosis.

That sounds intense, and it absolutely is.

Steatosis just means a fatty liver.

So what happens is these drugs can cause mitochondrial toxicity.

The mitochondria are the power plants of our cells.

Exactly.

If the NRTIs mess with them, your body's whole metabolism shifts.

You get a buildup of lactic acid in the blood, and your liver gets enlarged and fatty.

It's rare, but it can be fatal.

So unexplained abdominal pain, nausea, fatigue,

you have to investigate.

The text also mentions a really specific issue with hepatitis B co -infection.

This is critical.

So many HIV drugs, specifically imtricitabine, lamivudine, and tenofovir, also happen to treat hepatitis B.

So that sounds like a bonus, right?

Two birds, one stone?

It is a bonus until you stop the drug.

If a patient has both HIV and hep B, and for whatever reason they abruptly stop taking these medications, the hepatitis B can flare up, and I mean aggressively.

We call it a severe acute exacerbation of their hepatitis.

So the nursing implication is crystal clear.

Educate the patient to never ever stop these cold turkey, especially if they have hep B.

Got it.

Any other general side effects for the nukes?

Well, there's that concept of mitochondria toxicity that can lead to other issues, like peripheral neuropathy, that tingling burning pain in the hands and feet, and lipoatrophy.

Lipophatrophy, that's fat wasting, right?

Yes, a very distinct thinning of the fat in the face, arms, and legs.

It's less common with the newer drugs in this class, but it's historically associated with NRTIs.

Okay, moving on to the next class.

The NNRTIs,

the non -nukes.

The non -nucleoside reverse transcriptase inhibitors.

So how are these different from the nukes?

They both target the same enzyme.

They do, but in a totally different way.

So if the nukes are fake building blocks that stop construction,

the non -nukes are like jamming a piece of gum in the lock of the enzyme itself.

Ah, I like that.

They bind directly to the reverse transcriptase enzyme at a different site and just jam it up.

They don't pretend to be anything, they just physically block the machinery so it can't work.

Okay, so what are the pros and cons here?

Well, a pro is that they save other classes, like the powerful protease inhibitors, for later use if needed.

And they often have a lower pill burden.

The big con, though, is that they have a low genetic barrier to resistance.

Meaning the virus figures them out pretty quickly.

Very quickly.

If you miss just a few doses, the virus can easily mutate around that gum in the lock and keep working.

The adherence for this class has to be absolutely perfect.

The prototype drug the book focuses on here is efeverence, E -F -V.

This one has some really distinct side effects, right?

It does.

When you think of Feverence, you have to think CNS central nervous system symptoms.

Dizziness, sedation,

and really vivid nightmares or dreams.

Vivid nightmares.

You hear that from patients.

Oh, yeah.

Intense dreams, sometimes euphoria,

difficulty concentrating.

The text mentions that because it penetrates the cerebrospinal fluid so well, you get these really prominent neuropsychiatric effects.

And there's a specific way to take it to minimize this, right?

Patient teaching point.

Yes.

Two things.

One, take it at bedtime so you can sleep through the worst of the dizziness.

And two,

this is crucial.

Take it on an empty stomach.

Why empty?

Usually it's take with food to avoid upset stomach.

Not with this one.

Because high fat meals dramatically increase the absorption of Efeverence.

If you absorb too much at once, you get toxicity.

So if you eat a big greasy meal like a double cheeseburger and then take your Efeverence, you are jacking up the drug level in your blood significantly, which makes those bad CNS side effects so much worse.

The no double cheeseburger rule.

I'll definitely remember that.

Yeah.

What about pregnancy with Efeverence?

There is a known history of neural tube defects reported in primate studies.

So we exercise a lot of caution, especially in the first trimester.

It always involves a very serious risk benefit discussion with the patient.

Now, generally for the non -nukes as a class, there's a skin issue we need to be watching for.

It's a very common side effect.

But you have to monitor it closely because it can escalate to Stevens -Johnson syndrome or SJS, which is a life -threatening skin necrosis.

Any rash with a fever or blisters is a medical emergency.

And interactions.

The list is huge.

These drugs are heavily metabolized by the CYP3A4 system in the liver, so they interact with a ton of other medications.

And this is where it gets really interesting with some over -the -counter stuff.

St.

John's Wort.

Ah, yes.

The herbal supplement.

Patients often take it for mild depression, thinking it's natural and harmless.

But St.

John's Wort induces those liver enzymes, meaning it makes the liver chew up the HIV drugs way too fast.

It tanks the level.

So it makes the HIV medicine not work.

Exactly.

It reduces the efficacy.

So St.

John's Wort is an absolute no -go.

And Rilpivirin, another non -nuke, has a specific contraindication with antacids.

This seems important.

Extremely important.

Specifically with proton pump inhibitors, or PPIs, like omeprazole, Rilpivirin means a very acidic environment in the stomach to be absorbed properly.

If you take a PPI, you neutralize the acid, you kill the absorption of the drug, and the virus wins.

Okay, let's switch gears.

The third major class.

The protease inhibitors, PIs.

These are cool.

They act at the very end of the virus's life cycle.

Okay, explain that.

What's happening at the end?

So the virus has already used reverse transcriptase.

It's integrated its DNA, and it's used the cell to create these long polyprotein strands.

But to become a new infectious virus particle, those strands need to be cut into specific functional pieces.

Like cutting a ribbon at a ceremony to open something.

Exactly.

The enzyme protease acts as the molecular scissors.

And protease inhibitors, well, they jam the scissors.

So the new virus particles are released from the cell, but they're broken.

They're immature.

They're basically duds.

They float away.

But they cannot infect a new cell.

They're non -functional.

Now with PIs, we have this concept of boosting.

We almost always see them given with drugs like Ritonavir or Cobe -Cistat.

Why do we add that second drug?

It's a brilliant pharmacokinetic enhancement strategy.

Ritonavir is technically a PI itself.

But we often use it in very low doses, not to kill the virus directly, but to inhibit the liver enzyme, CyT3 -3A4, again.

That breaks down the other more powerful PI in the regimen.

So Ritonavir basically takes the hit from the liver so the main drug can survive longer and at a higher concentration.

Perfectly said.

It keeps the blood levels of the primary PI high and stable.

This allows for lower doses of the main drug and less frequent pill popping, which is a huge win for adherence.

OK.

Let's talk about the prototype from the book.

Adazanavir.

ATV?

Adazanavir.

With this one, you need to watch the heart.

It can cause PR interval prolongation, which is essentially a type of heart block.

You'd want to be cautious in patients with underlying cardiac conditions.

And what about metabolically?

PIs, as a class, are notorious for causing metabolic syndrome -like effects.

Hyperglycemia, high blood sugar, which can lead to new onset diabetes.

And hyperlipidemia, high cholesterol, and triglycerides.

And the fat redistribution thing.

I've heard about this.

Yes, lipodystrophy.

It's a bit different from the lipoatrophy with the nukes.

With PIs, you can get fat accumulation.

You might hear about buffalo hump, which is fat accumulating on the back of the neck.

Or protease paunch, which is central obesity.

It physically changes the patient's body shape, which can be really distressing and a huge barrier to adherence.

And interactions.

Sounds like another long list.

PIs inhibit CYP450, so the interaction list is a mile long.

Statins are a big one.

You have to avoid simvastatin and levastatin, because the PI will boost their levels to a dangerous point, increasing the risk of rhabdomyolysis' severe muscle breakdown.

And garlic.

Believe it or not, yes.

Garlic supplements can lower PI levels.

So you have to tell your patients, no garlic pills.

Cooking with garlic is fine, but not the concentrated supplements.

Okay, we're moving right through the life cycle.

We've done the nukes, the non -nukes, the PIs.

Now let's talk about the drugs that stop the virus from even getting in the door.

The entry inhibitors.

Right, so this class is broken down into two main types.

Fusion inhibitors and CCR5 antagonists.

Let's start with the fusion inhibitor.

The book names in fuvertide, T20.

So this drug literally blocks the fusion of the virus to the cell membrane.

It stops it from latching on and getting inside.

But here's the catch.

It's a subcutaneous injection, twice a day.

An injection.

Wow, that is a tough sell for a daily maintenance drug.

It is.

It's generally used as salvage therapy, when other oral treatments have failed due to resistance.

And the adverse effects are pretty rough.

The text says 98 % of patients get injection site reactions.

98%.

Nodules, cysts, hardening of the skin.

It's a tough drug to be on.

Ouch.

Okay, what about the other type?

The CCR5 antagonist, Marvarac.

So this one blocks the doorway.

The HIV virus usually needs to grab onto a co -receptor on the cell surface called CCR5 to get in.

Marvarac basically puts a cover over that receptor so the virus can't use it.

But not all strains of HIV use that same door, right?

Exactly right.

Some HIV strains use a different doorway called CXCR4.

So before you can even prescribe Marvarac, you have to do a specific blood test called a tropism assay.

To see which door that particular patient's virus is using.

Precisely.

If their virus uses CXCR4, this drug is completely useless for them.

It has a black box warning for hepatotoxicity too, so you're watching those liver enzymes.

And finally, the newest heavy hitters on the block.

The NSTIs.

The integrase strand transfer inhibitors.

Yes.

Raltogravir, dilutogravir, lvitogravir.

These prevent the viral DNA from integrating itself into the human host cell's DNA.

So this is stopping the final mind melt where the virus becomes a permanent part of our genetic code.

Essentially, yes.

And these are now a recommended first line agent in many guidelines because they're very potent and generally much better tolerated than the older classes.

But there is a weird interaction with vitamins and antacids, right?

Yes.

This is a huge patient education point.

Polyvalent -cations.

Think magnesium, iron, calcium, aluminum.

If you take a multivitamin or an antacid like Tums with your NSTI, the drug will literally bind to the metal in your stomach and won't get absorbed.

So you just coop it out?

Basically.

You have to separate the doses by at least two hours before or six hours after.

And side effects?

Any big ones?

Generally well tolerated, but you can see insomnia and headache.

The rare but serious one to watch for is muscle problems like myopathy or even rhabdomyolysis.

So if a patient on an NSTI complains of new severe muscle pain, you absolutely need to investigate it.

Phew.

Okay.

That is a lot of pharmacology.

But as we know, the best drug in the world doesn't work if the patient doesn't take it.

Which brings us to section seven.

The nurse's role.

This is it.

This is where the science meets the human element.

The golden rule of adherence.

What's the actual requirement?

How good is good enough?

Here, 100%.

100%.

That seems impossible for any human being over the course of decades.

It is an incredibly high bar.

But with HIV, because of that rapid mutation rate we discussed,

studies show that dropping below 95 % adherence correlates very strongly with the development of drug resistance.

Missing just two or three doses a month can be enough to burn an entire drug regimen forever.

So the nurse's job isn't just to hand over the pills and say good luck.

It's to be a detective.

A detective, a partner, a problem solver.

You have to assess the barriers.

Is it stigma?

Are they hiding the pills from a roommate or partner?

Is it cost?

Is it pill fatigue?

Pill fatigue is so real.

I can't imagine getting tired of swallowing meds every single day for the rest of your life.

It's a huge factor.

So we have to use tools.

Pill planners, alarms on their phone.

The text even suggests using medication maps with pictures of the pills for patients who might have lower literacy or cognitive issues.

And as a nurse, we need to differentiate between side effects of the drugs and symptoms of the disease.

That's a crucial point.

If a patient feels sick, their first instinct might be to stop the meds, thinking the meds are the problem.

We need to help them figure out is it the drug causing some initial nausea or is this the first sign of an opportunistic infection?

Speaking of things getting worse before they get better, let's talk about IRIS, Immune Reconstitution Inflammatory Syndrome.

This is a fascinating and frankly somewhat scary phenomenon.

So you start a patient on RT.

Their immune system, which has been asleep at the wheel or beaten down for years, suddenly wakes up.

And it comes out swinging.

It really does.

And if there's a dormant subclinical infection hiding in the body, say a little bit of TB or a fungal infection that the weakened body was just ignoring,

the newly awakened immune system attacks it with full force.

So the patient actually gets sicker after starting the treatment that's supposed to make them better.

For a time, yes.

That's IRS.

It creates this massive over -the -top inflammatory response.

High fevers, worsening symptoms.

It's confusing and scary for them.

And there are two types, right?

The text mentions paradoxical and unmasking.

Paradoxical is when we already know about an infection, we're treating it, but it suddenly gets much, much worse after starting RT.

Unmasking is when a hidden, previously undiagnosed infection reveals itself because the immune system finally notices it's there.

So what do we do?

Do we stop the HIV meds?

Usually no.

And that's the key.

We treat the opportunistic infection aggressively.

We might use corticosteroids to calm down the inflammation, but we try to keep the art going unless the iris is truly life -threatening.

We do not want that viral load to rebound.

Okay, moving on to Section 8.

The opportunistic infections themselves.

We treat everyone to prevent these, but they still happen, especially in that 13 % who are undiagnosed.

They do.

Or in those with poor adherence.

They are still the leading cause of death in people with advanced HIV.

Let's do a rapid -fire overview of the big ones listed in the text.

First up, Pneumocystis geroveci pneumonia, or PJP.

It's actually a fungus, but oddly enough, the treatment and prophylaxis is with an antibacterial.

Trimethoprim sulfamethoxazole.

You probably know it as Bactrim receptor.

Next,

tuberculosis, TB.

Oh, TB is so tricky because of the drug interactions.

The drugs used for TB, particularly the rifamycins like rifinpin, are potent enzyme -inducers.

They make the liver chew up the HIV meds, especially PIs and NNRTIs.

So managing a patient with both TD and HIV requires a specialist to carefully balance all the drugs.

Kaposi sarcoma.

This is the hallmark visible sign of AIDS from the early days of the epidemic.

Those dark blue or purple lesions on the skin, in the mouth, or even in the lungs.

We can treat it with chemotherapy or radiation, but the best treatment is getting the immune system back online with effective art.

Cytomegalovirus or CMV.

This one is scary because it causes retinitis.

It can cause blindness.

If a patient with a low CD4 count complains of blurred vision or floaters, that is a medical emergency.

We treat it with antivirals like Gansaclover.

And finally, MSE, mycobacterium avium complex.

This is a disseminated blood infection.

You see drenching, night sweats, high fevers, wasting syndrome.

We treat with macrolides azithromycin or clarithromycin.

Okay, section nine, special populations.

Pregnancy.

This is a huge success story in the world of HIV management.

It really is.

It's incredible.

Without art, the risk of a mother passing HIV to her baby is about 25%.

One in four.

Yes.

With successful art and a suppressed viral load, that risk drops to less than 1%.

Some studies say less than 2%, but it's a dramatic reduction.

That is just amazing.

So the protocol is just continue the meds.

Absolutely.

Continue our art.

The goal is maximal viral suppression to protect the baby.

Now, if the mother's viral load is still high specifically, the text says over 400 copies per milliliter near the time of delivery.

We administer Cifava zitavudin during labor.

For extra protection.

Exactly.

To provide extra protection for the baby during that high risk moment of birth.

And regarding if averns in pregnancy, which we touched on.

Right.

Again, because of that historic neural tube defect risk, we have a very serious risk benefit discussion, especially in the first trimester.

But in many cases, the benefit of suppressing the virus for the mother's health outweighs the potential risk.

What about occupational exposure?

The dreaded needle stick.

It happens.

This is where PEP comes in, post -exposure prophylaxis.

What's the timeline on that?

How quickly do you need to act?

Time is tissue, or in this case, time is T cells.

You need to initiate the medication within 72 hours, ideally much, much sooner, within hours if possible.

And how long do you have to take the meds?

It's a four -week course of a three -drug regimen.

And let me tell you, adherence is hard even for health care workers who know the risks, because these drugs can make you feel nauseous and fatigued.

But you absolutely have to finish the course.

Okay, we are in the home stretch.

Section 10, clinical judgment.

The text gives us a great case study of a 35 -year -old female.

Let's try to role play this a little bit.

She's newly diagnosed.

She had a recent flu -like illness.

So that tells us she's probably in the acute stage.

Right, stage one.

Highly infectious.

And she tells the nurse she missed some doses because she went on a trip for the weekend.

That is a classic scenario.

The travel disruption.

Any change in routine is a high -risk time for non -adherence.

So how does a nurse handle that?

You don't just scold them, right?

No, never.

You problem -solve.

You say, okay, you love to travel.

That's great.

Let's make a plan for that.

How can we pack your meds so they're always with you?

Do you need a travel alarm?

Do you need a special pill box that fits in your carry -on?

Make it a collaboration.

She also mentions in the case study that she was monogamous.

So she didn't think she was at risk.

And this is a huge teaching moment about the myths.

Monogamy only protects you if both partners are tested and confirmed negative.

You can be monogamous to a partner who isn't or who has an undiagnosed history from before your relationship.

The virus doesn't care about relationship status.

And she asks the question every single newly diagnosed patient asks.

Why do I have to take three different drugs?

It's so many pills.

And that is where you use the analogy we talked about.

You say, imagine the virus is a really smart army.

If we just build one wall, they'll figure out how to climb over it.

But if we build a wall and we dig a moat and we put archers on the tower,

they can't get through.

I love that.

We attack the virus at different stages.

When it tries to get in, when it tries to copy itself, when it tries to assemble new soldiers to make sure it can't survive.

That is such a great explanation for a patient.

It helps them understand that the complexity of the regimen isn't arbitrary.

It's strategic.

Exactly.

It gives them buy -in.

So bringing it all together as we wrap up, we've covered the entire life cycle of the virus and how each drug class matches up to a specific step.

Right.

Entry inhibitors block the door.

NRTIs and NNRTIs stop the building of the viral DNA.

NSTIs stop that DNA from melding with ours.

And the PIs stop the final assembly of the new virus particles.

It's a full -court press attacking it from every angle.

And the nurse is the coach on the sidelines, managing the side effects, encouraging the adherents, spotting those OIs before they get out of hand, and providing that human support.

I want to leave our listeners with a final thought, something to chew on.

We talked about pill fatigue.

It's something I think about a lot, actually.

We have successfully turned a fatal disease into a chronic one.

That is a miracle of modern science.

But asking someone to take medication perfectly, every single day for 30, 40, maybe 50 years, that requires a level of human discipline that is just extraordinary.

It really, really does.

And as nurses, our job isn't just to know the creatinine clearance dose adjustment for tenofovir.

It is to understand the human burden of that discipline.

How do we keep that motivation, that hope alive for decades?

I think that's the real challenge of the next generation of HIV care.

That is a powerful place to leave it.

Thank you so much for breaking all of this down with us today.

This was incredibly helpful.

It was my pleasure.

And to all of you listening, thank you for tuning in.

Don't forget to check those tables in chapter 32.

Specifically, table 32 .1 for all the specific dosage nuances and drug names we didn't have time to list out.

This has been the Last Minute Lecture Team.

Signing off.

Stay curious, everyone.